Maxim analyst Jason McCarthy initiated coverage of Zevra Therapeutics with a Buy rating and $12 price target. Based on the combination of strong balance sheet, management team, and several key events ahead, the stock looks "undervalued", the analyst tells investors in a research note. Maxim further cites Zevra’s re-filing of new drug application NDA for arimolomol for treatment of Niemann-Pick disease type C expected in Q3 as well as its ongoing phase 2 trial of KP1077 in idiopathic hypersomnia, with interim data expected in Q3 and top-line results expected by the end of this year.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZVRA:
- Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
- Zevra Therapeutics announces collaboration with RARE-X, Sleep Consortium
- Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
- Zevra Therapeutics urges shareholders to vote for all director nominees
- Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
